Literature DB >> 22668774

Predictors of failure in timely tuberculosis treatment completion, United States.

K Mitruka1, C A Winston, T R Navin.   

Abstract

SETTING: The US tuberculosis (TB) surveillance system.
OBJECTIVE: To examine failure in timely TB treatment completion to identify interventions toward achieving the national goal of ≥ 93% treatment completion in ≤ 12 months among patients eligible for 6-9 month regimens.
DESIGN: We examined 1993-2006 trends in timely treatment completion; for 2006 cases, we used Poisson regression to assess predictors for failure in timely completion.
RESULTS: Timely treatment completion improved from 64% in 1993 to 84% in 2006, with similar trends among foreign- and US-born persons and racial/ethnic subgroups. Annual increases in timely completion were ≤ 1 percentage point during 1998-2006. Subpopulations at highest risk for failure in timely completion were persons with combined pulmonary and extra-pulmonary disease (foreign-born adjusted RR [aRR] 3.25, 95%CI 2.47-4.28; US-born aRR 2.75, 95%CI 1.98-3.83) or incarceration (foreign-born aRR 2.30, 95%CI 1.80-2.93; US-born aRR 1.71, 95%CI 1.36-2.14). Homelessness and human immunodeficiency virus infection were other risk factors.
CONCLUSIONS: Particular attention to timely completion is needed for subpopulations requiring strong medical expertise in TB management and those at risk for treatment non-adherence, especially if foreign-born. Understanding and addressing causes of delayed completion and improving documentation of treatment completion among all cases will be crucial to achieving the US goal.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22668774     DOI: 10.5588/ijtld.11.0814

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  17 in total

1.  Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

Authors:  Eleanor E Friedman; Hazel D Dean; Wayne A Duffus
Journal:  Public Health Rep       Date:  2018-06-06       Impact factor: 2.792

Review 2.  Systematic review of risk factors for nonadherence to TB treatment in immigrant populations.

Authors:  Stephanie Lin; G J Melendez-Torres
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-05       Impact factor: 2.184

3.  A tuberculosis outbreak fueled by cross-border travel and illicit substances: Nevada and Arizona.

Authors:  Kiren Mitruka; Haley Blake; Philip Ricks; Roque Miramontes; Sapna Bamrah; Carla Chee; Laurie Hickstein
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

4.  Tuberculosis trends in California correctional facilities, 1993-2013.

Authors:  C J McDaniel; A S Chitnis; P M Barry; N Shah
Journal:  Int J Tuberc Lung Dis       Date:  2017-08-01       Impact factor: 2.373

5.  Impact of Targeted Local Interventions on Tuberculosis Awareness and Screening Among Persons Experiencing Homelessness During a Large Tuberculosis Outbreak in Atlanta, Georgia, 2015-2016.

Authors:  Eleanor M Kerr; Laura A Vonnahme; Neela D Goswami
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

6.  Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.

Authors:  Charlotte Wheeler; Janet Mohle-Boetani
Journal:  Public Health Rep       Date:  2019 May/Jun       Impact factor: 2.792

7.  Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis.

Authors:  A C Pettit; J Cummins; L A Kaltenbach; T R Sterling; J V Warkentin
Journal:  Int J Tuberc Lung Dis       Date:  2013-02-07       Impact factor: 2.373

8.  Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis.

Authors:  A Singanayagam; K Manalan; D W Connell; J D Chalmers; S Sridhar; A I Ritchie; A Lalvani; M Wickremasinghe; O M Kon
Journal:  Int J Tuberc Lung Dis       Date:  2016-12       Impact factor: 2.373

9.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

10.  Treatment duration for patients with drug-resistant tuberculosis, United States.

Authors:  Carla A Winston; Kiren Mitruka
Journal:  Emerg Infect Dis       Date:  2012-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.